WEGOVY® (SEMAGLUTIDE INJECTION) RECEIVES CONDITIONAL MARKETING AUTHORIZATION FROM HEALTH CANADA AS THE FIRST AND ONLY TREATMENT FOR ADULTS WITH NON-CIRRHOTIC MASH, A SERIOUS LIVER DISEASE

Reuters · 3d ago

Please log in to view news